Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Waters logoWaters WAT

Waters said total reported revenue for Q1 2026 was $1.267 billion, including organic revenue of $747 million and revenue of $520 million from the Biosciences and Diagnostic Solutions businesses acquired from Becton, Dickinson and Company. Organic revenue grew 13% as reported and 11% in constant currency.

8-KResults of Operations and Financial ConditionFiled Period of report Summary published (UTC)

Key points

AI summary
  1. Waters said total reported revenue for Q1 2026 was $1.267 billion, including organic revenue of $747 million and revenue of $520 million from the Biosciences and Diagnostic Solutions businesses acquired from Becton, Dickinson and Company. Organic revenue grew 13% as reported and 11% in constant currency.

  2. The company said it reported a GAAP diluted loss per share of $0.87 for Q1 2026, compared with diluted EPS of $2.03 a year earlier. It cited purchase accounting charges tied to the acquisition, including amortization of acquired intangibles and inventory step-up, as the reason. Adjusted EPS rose 20% to $2.70.

  3. Waters said it is raising its full-year 2026 adjusted EPS guidance to $14.40 to $14.60, which it said represents growth of 10% to 11% over the prior year. It also gave full-year reported revenue guidance of $6.405 billion to $6.455 billion.

  4. The company said net cash used in operating activities for Q1 2026 was $(3) million, and adjusted free cash flow, a non-GAAP measure, was $(42) million. Over the same period, it had proceeds from debt issuances of $3,530 million and payments on debt of $3,700 million.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Q1 Revenue $1.267 billion, Organic Revenue Up 13%

Waters said total reported revenue for Q1 2026 was $1.267 billion, including organic revenue of $747 million and revenue of $520 million from the Biosciences and Diagnostic Solutions businesses acquired from Becton, Dickinson and Company. Organic revenue grew 13% as reported and 11% in constant currency.

Source · Based on the filing body and exhibits

GAAP Diluted Loss Per Share ($0.87), Adjusted EPS $2.70

The company said it reported a GAAP diluted loss per share of $0.87 for Q1 2026, compared with diluted EPS of $2.03 a year earlier. It cited purchase accounting charges tied to the acquisition, including amortization of acquired intangibles and inventory step-up, as the reason. Adjusted EPS rose 20% to $2.70.

Source · Based on the filing body and exhibits

Full-Year Adjusted EPS Guidance Raised to $14.40 to $14.60

Waters said it is raising its full-year 2026 adjusted EPS guidance to $14.40 to $14.60, which it said represents growth of 10% to 11% over the prior year. It also gave full-year reported revenue guidance of $6.405 billion to $6.455 billion.

Source · Based on the filing body and exhibits

Q1 Operating Cash Flow $(3) million, Free Cash Flow $(42) million

The company said net cash used in operating activities for Q1 2026 was $(3) million, and adjusted free cash flow, a non-GAAP measure, was $(42) million. Over the same period, it had proceeds from debt issuances of $3,530 million and payments on debt of $3,700 million.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.